Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DXC006 + immune checkpoint inhibitor
- Development stage
- Unknown
- Lead developer
- Hangzhou DAC Biotech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DXC006 + immune checkpoint inhibitor is an investigational combination therapy being developed for the treatment of small cell lung cancer (SCLC). DXC006 is an antibody-drug conjugate (ADC) developed by Hangzhou DAC Biotechnology that targets Delta-like ligand 3 (DLL3), a protein frequently overexpressed in SCLC and other neuroendocrine tumors. The ADC comprises a DLL3-specific monoclonal antibody conjugated to a potent cytotoxic payload, typically a DNA topoisomerase I inhibitor (such as an exatecan derivative), via a cleavable linker. By combining DXC006 with an immune checkpoint inhibitor (ICI) targeting the PD-1 or PD-L1 pathway, the regimen aims to achieve synergistic anti-tumor effects through direct ADC-mediated cytotoxicity and the restoration of anti-tumor immunity. This combination is currently under evaluation in Phase Ib/II clinical trials (NCT06344104) to assess its safety, tolerability, and preliminary efficacy in patients with SCLC.
- Other names
- DXC006 plus immune checkpoint inhibitorDXC-006 plus immune checkpoint inhibitorDXC 006 plus immune checkpoint inhibitor
02
Targets
NCAM1 (Neural cell adhesion molecule 1)TOP1 (DNA Topoisomerase I)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)DLL3 (Delta-like ligand 3)
Beyond the preview
Go deeper on DXC006 + immune checkpoint inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DXC006 + immune checkpoint inhibitor.